Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Japan Hepatitis C Settlement Set To Cover Only 10 Percent

This article was originally published in PharmAsia News

Executive Summary

The Japanese government settlement with hepatitis C patients, set for Osaka High Court review Feb. 7, is likely to cover only 10 percent of those infected, according to a plaintiff lawyer. The lawyer said the others have not been able to prove the source of their infection and probably will not be covered. The cases were linked to blood products provided by Mitsubishi Tanabe Pharma, but many patient records were destroyed before a connection could be determined. Mitsubishi Tanabe's Green Cross unit, a defendant in one suit, is to share in the settlement payout. (Click here for more

Table

View full table

Tags:
Latest Headlines

Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

Competition Forces Price Cuts, But Novo Nordisk Is Unstoppable

Metagenomi Looks For Upside To Moderna’s Exit

Executives On The Move: Senior Moves At Innovent Biologics, Actym Therapeutics And Enanta Pharmaceuticals

See All
UsernamePublicRestriction

Register

SC066632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By